Perspective Therapeutics, Inc. short interest in 2019
In 2019, Perspective Therapeutics, Inc.'s disclosed short interest ran from 1.63% of shares outstanding on 15 Jan 2019 to 2.45% on 31 Dec 2019, a change of +0.82 percentage points. The year's high was 2.61% on 13 Dec 2019 and its low 0.74% on 31 Jul 2019, averaging 1.53% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.37 days on 15 Oct 2019. Full history: Perspective Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2019 in figures
- Start of year
- 1.63% (15 Jan 2019)
- End of year
- 2.45% (31 Dec 2019)
- Change
- +0.82 pp
- High
- 2.61% (13 Dec 2019)
- Low
- 0.74% (31 Jul 2019)
- Average
- 1.53%
- Highest days to cover
- 18.37 (15 Oct 2019)
- SEC filings marked
- 8
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 1.63% | 10.83 | |
| 31 Jan 2019 | 1.58% | 3.05 | |
| 15 Feb 2019 | 1.52% | 4.54 | results (8-K), 10-Q filed |
| 28 Feb 2019 | 1.38% | 3.23 | |
| 15 Mar 2019 | 1.31% | 11.21 | |
| 29 Mar 2019 | 1.26% | 9.96 | |
| 15 Apr 2019 | 1.23% | 6.83 | |
| 30 Apr 2019 | 1.15% | 4.32 | |
| 15 May 2019 | 1.28% | 6.06 | results (8-K), 10-Q filed |
| 31 May 2019 | 0.97% | 2.93 | |
| 14 Jun 2019 | 1.03% | 5.78 | |
| 28 Jun 2019 | 0.87% | 6.37 | |
| 15 Jul 2019 | 0.94% | 8.96 | |
| 31 Jul 2019 | 0.74% | 5.46 | |
| 30 Sep 2019 | 2.04% | 4.05 | results (8-K), 10-K filed |
| 15 Oct 2019 | 1.98% | 18.37 | |
| 31 Oct 2019 | 1.94% | 17.91 | |
| 15 Nov 2019 | 2.04% | 4.98 | results (8-K), 10-Q filed |
| 29 Nov 2019 | 2.27% | 2.32 | |
| 13 Dec 2019 | 2.61% | 2.46 | |
| 31 Dec 2019 | 2.45% | 7.04 |
See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.